Nancy Thiex opened the meeting. After introductions the following issues were covered:
Approval of Agenda – The agenda was approved (enclosed).

Approval of Minutes from the August Meeting – The Minutes from the meeting held on August 6, 2006 in Oklahoma City, OK (attached) were approved with the following corrections:

- The meeting took place August 6, 2006
- Sondra Flick did not volunteer to champion the Carbadox “Needs statement”. Alpharma does not carry this drug.

METHOD ISSUES

New Methods Survey results – Thiex summarized the outcome of the most recent survey.

Lasalocid Collaborative Study – Charles Focht reported that the results of the study would be presented during the AOAC meeting and that the study report had been submitted to AOAC Committee I for its approval.

Oxytetracycline Collaborative Study – Rich Larson reported that samples were sent to 17 labs and that 11 labs returned results. The data looked very good and would be presented during the meeting.

Multi-Analyte Mycotoxin Method – In Dr. Maria Ofitserova’s absence Laszlo Torma reported that a method involving HPLC Post column detection had been developed. He will present the results during the meeting. Dr. Maria Ofitserova has submitted the mycotoxin method and related data from Pickering Laboratories to Gary Lombaert, Harold Campbell, Chris Maragos, Nancy Thiex, and Laszlo Torma. The expert panel reviewed the method and related data and Gary Lombaert and Harold Campbell submitted written comments and suggestions on the method and the data presented to Nancy Thiex and other members of the panel. Laszlo Torma did not make a written review, but made comments and suggestions on behalf of Pickering Laboratories to the Feed Additives and Contaminant Group during the September 17, 2006 meeting. One of the major issues is that the method in its current form does not determine T2 toxin content which was one of the requirements listed in the method’s “need sheet”. The Committee agreed that the “needs sheet” reflects “wishful thinking” rather than “requirement for approval” and that validating any method representing the state of the art is a worthwhile undertaking even if it does not meet all of the parameters listed in the “needs sheet”. FB3 is not covered either – however this is more a result of difficulties in obtaining reference standards rather than method limitations. FB3 currently also has low regulatory concern and low rate of occurrence. The Committee unanimously voted to commend Ofitserova for all her work and encourage her and Pickering to proceed with the SLV (minus T2 and FB3), and to recommend the removal of needs statements from web sites following the approval of methods.

Laszlo Torma also stated that, if Pickering Laboratories will proceed the SLV, we will need help guiding us with the SLV process and securing naturally contaminated samples for the study.

The biggest challenge for the collaborative study is to obtain incurred samples.

Neomycin Method Study – Julee Driver is in the process of completing the SLV process. She will present the status of the project at the meeting.

Decoquinate Method Study – Anivis Sanchez has submitted the revised study protocol to AOAC Committee I for approval and sent 22 samples for homogeneity testing. These samples will be sent to participating labs following the approval of the protocol. Currently 11 labs have expressed an interest in participating.
Chlortetracycline Method Study – Jane Sabbatini reported that she is working on a modified version of the method provided by South Dakota Dept. of Ag. It works well on premixes. Sabbatini is currently checking the method’s applicability on feeds including correlating the results obtained from the HPLC method with the results obtained from the official plate micro assay method. The current main obstacle is method linearity. While the standard curve is linear, the intercept does not go through zero due to a baseline aberration at the retention time of chlortetracycline.

Multi-Analyte Elemental Method (with focus on metals) – Thiex distributed an updated version of the “needs statement”. It has been reviewed by Dr. Jerry Spears w/ U of North Carolina and his comments have been included in the current version of the document. The Committee unanimously voted to accept the “needs statement” in its current form. The next steps include asking for suggestions for methods and identifying a “champion” that will review the suggestions and draft up an analytical approach. The Committee agreed that multiple methods may be required in order to meet in order to meet the criteria expressed in the “needs sheet”.

Multi-Analyte Pesticide Residue Method(s) – Thiex reported that we need to identify a “Champion” interested in putting the needs statement together. Adrian Burns and Kevin Armbrust were suggested as good sources for leads for such individuals. Jo Marie Cook, Tom Phillips, Steven Lehotay (USDA), Randy Lovell (FDA) may be interested. The likely first method under consideration will be the QuEChERS method.

Vitamin A Method Needs Statement – The updated draft statement provided by Ken Riter was reviewed. Precision and recovery performance criteria has been made concentration dependent. It was suggested that Neil Craft w/ Craft Technologies be involved together with representatives from Adisseo, DSM and BASF (Reimann to provide contact information). Some discussion followed as to the method performance needs, especially CVs. Also concerns about the conversion of all-trans to 13-cis during the extraction process and whether the method should be able to separate the two compounds. Riter will ask John McDonald to review document and Thiex will send the document to AGLABS subscribers for feedback. Comments should be sent to Riter (ken.riter@purina.nestle.com).

Tylosin Needs Statement – Mark Coleman is in the process of drafting a “needs statement”.

Amprolium Method Needs Statement – Harold Campbell’s draft of a method needs statement needs to be reviewed by a FDA representative as well as representatives for the manufacturers/distributors for this compound in the US. Dennis McCurdy offered to review the draft from a FDA perspective. Sabbatini and Reimann offered to check with Phibro and Merial respectively for the appropriate contact person and provide Campbell with this information (hcampbell@inspection.gc.ca).

Vit D and E Needs Statement – Ken Riter, Victoria Siegel and Michelle Campbell all expressed an interest in initiating this project.

Carbadox Needs Statement – Jane Sabbatini volunteered to draft a needs statement including contacting Alex MacDonald w/ Phibro for feedback (Phibro is the US manufacturer and distributor of carbadox). The question was raised if the needs statement should target pyrantel tartrate as well since published methods appear to cover both compounds.

MGA Needs Statement – Jon Dalgleish volunteered to draft the “needs statement”.

Bacitracin Needs Statement – Sondra Flick is in the process of drafting the needs statement.
OTHER ISSUES

AOAC Feed Additives and Contaminant Subgroup Website – http://www.aoac.org/Aq_materials/additives/main.htm. Access to the site does not currently require AOAC membership. LuAnn Wetzler volunteered to update the web site. Access to the AAFCO Lab Committee website on foodshield.org currently does require a password and ID.

Report from the Quality Sub-Group – Louise Ogden reported that the group had reviewed the AOAC-ALACC document and, decided it was not suitable for accrediting feed labs against, and sent a letter to AOAC with this message. Instead the group has decided to revise the AAFCO “Quality Assurance/Quality Control Guidelines for State Feed Laboratories” to comply with the ISO format including adding a chapter on “Uncertainty”. The group is meeting monthly through conference calls and showing good progress. It hopes to have a draft available for general review at the January AAFCO meeting. It was noted that the current ALACC Guidelines still cover food testing labs. Anyone interested in participating in this project should contact Louise Ogden.

Future workshops – No news.

Future Symposium – Thiex will try to have AOAC provide a ½ day Symposium slot at the next annual meeting.

FDA Method Submission – This issue addresses how to get FDA’s acceptance of AOAC validated methods as appropriate alternate methods for regulatory compliance testing. At the January meeting the decision was made to use the sulfamethazine method collaborated by Bob Smallidge as a pilot for this project. Victoria Siegel reported that she had spoken with Linda Benjamin, FDA who had stressed the importance of following processes and protocols for this task. Siegel will maintain detailed notes of the activities involved with the intent that they can form a road map for how to efficiently execute similar projects in the future. Siegel also reported that the raw data for the study had been recovered from Dr. Smallidge’s attic. Siegel will meet in the near future with Elanco’s Regulatory specialists for assistance in the preparation of the appropriate submission package. Concerning other methods in the pipeline – Thiex will ask Alpharma to be a co-sponsor of the updated methods for lasalocid and decoquinate, Sabbatini will ask Phibro concerning amprolium, neomycin and oxytetracycline, Reimann will ask Merial about amprolium and Tom Phillips will ask PennField about neomycin and oxytetracycline.

AAFCO Committee Leadership Issues – Thiex reported that considering the variety of activities undertaken by this committee it was impossible for her to manage all these by herself in an efficient fashion. Ed Moore had prior to his recent retirement been a great help to her and she is looking for someone to take on the role as Vice Chair. Thiex also suggested that the leadership responsibilities be further divided among more volunteers willing to manage other tasks such as workshops and method validation activities. She is approaching AAFCO with suggestions for institutionalizing such positions.

Respectfully submitted,

Lars Reimann

Eurofins Scientific, Inc.